TWI598098B - 脂質異常症治療劑 - Google Patents

脂質異常症治療劑 Download PDF

Info

Publication number: TWI598098B
Authority: TW; Taiwan
Prior art keywords: group; cholesterol; hdl; ezetimibe; compound
Prior art date: 2012-09-27

Application number

TW102134981A

Other languages

English (en)

Chinese (zh)

Other versions

TW201417811A (zh

Inventor

瀧澤俊明

吉中康展

Original Assignee

興和股份有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-27

Filing date

2013-09-27

Publication date

2017-09-11

2013-09-27 Application filed by 興和股份有限公司 filed Critical 興和股份有限公司

2014-05-16 Publication of TW201417811A publication Critical patent/TW201417811A/zh

2017-09-11 Application granted granted Critical

2017-09-11 Publication of TWI598098B publication Critical patent/TWI598098B/zh

Links

239000003814 drug Substances 0.000 title description 14
208000032928 Dyslipidaemia Diseases 0.000 title 1
208000017170 Lipid metabolism disease Diseases 0.000 title 1
229940124597 therapeutic agent Drugs 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 90
150000002632 lipids Chemical class 0.000 claims description 58
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 57
229960000815 ezetimibe Drugs 0.000 claims description 54
230000005856 abnormality Effects 0.000 claims description 51
235000012000 cholesterol Nutrition 0.000 claims description 45
239000008194 pharmaceutical composition Substances 0.000 claims description 31
150000003839 salts Chemical class 0.000 claims description 28
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 24
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 21
206010012601 diabetes mellitus Diseases 0.000 claims description 16
208000001145 Metabolic Syndrome Diseases 0.000 claims description 13
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 13
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 12
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
230000002265 prevention Effects 0.000 claims description 6
230000001737 promoting effect Effects 0.000 claims description 2
239000002253 acid Substances 0.000 claims 1
125000005456 glyceride group Chemical group 0.000 claims 1
150000001875 compounds Chemical class 0.000 description 51
229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 33
229940126062 Compound A Drugs 0.000 description 28
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 28
239000012453 solvate Substances 0.000 description 23
239000003795 chemical substances by application Substances 0.000 description 22
239000008280 blood Substances 0.000 description 21
210000004369 blood Anatomy 0.000 description 21
-1 mercaptooxy group Chemical group 0.000 description 21
238000000034 method Methods 0.000 description 18
230000000694 effects Effects 0.000 description 16
238000008214 LDL Cholesterol Methods 0.000 description 15
235000005911 diet Nutrition 0.000 description 11
230000037213 diet Effects 0.000 description 11
208000006575 hypertriglyceridemia Diseases 0.000 description 11
125000004430 oxygen atom Chemical group O* 0.000 description 8
102000023984 PPAR alpha Human genes 0.000 description 7
108010028924 PPAR alpha Proteins 0.000 description 7
108010069201 VLDL Cholesterol Proteins 0.000 description 7
229940079593 drug Drugs 0.000 description 7
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 7
229960002297 fenofibrate Drugs 0.000 description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
239000000203 mixture Substances 0.000 description 7
108091007403 Cholesterol transporters Proteins 0.000 description 6
230000001906 cholesterol absorption Effects 0.000 description 6
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
208000035150 Hypercholesterolemia Diseases 0.000 description 5
125000003545 alkoxy group Chemical group 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000037396 body weight Effects 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000012360 testing method Methods 0.000 description 4
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
208000011775 arteriosclerosis disease Diseases 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
235000003642 hunger Nutrition 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000004731 jugular vein Anatomy 0.000 description 3
229960001412 pentobarbital Drugs 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000036186 satiety Effects 0.000 description 3
235000019627 satiety Nutrition 0.000 description 3
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 3
235000021055 solid food Nutrition 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 description 2
108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 2
102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 2
108010013563 Lipoprotein Lipase Proteins 0.000 description 2
102000043296 Lipoprotein lipases Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
125000004414 alkyl thio group Chemical group 0.000 description 2
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
230000001174 ascending effect Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
229940125753 fibrate Drugs 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
125000004434 sulfur atom Chemical group 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
DEMLYXMVPJAVFU-UHFFFAOYSA-N 2-(chloromethyl)oxirane;2-methyl-1h-imidazole Chemical compound ClCC1CO1.CC1=NC=CN1 DEMLYXMVPJAVFU-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000002249 Diabetes Complications Diseases 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000057248 Lipoprotein(a) Human genes 0.000 description 1
108010033266 Lipoprotein(a) Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108020005497 Nuclear hormone receptor Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
125000005530 alkylenedioxy group Chemical group 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000002490 intestinal epithelial cell Anatomy 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
102000006255 nuclear receptors Human genes 0.000 description 1
108020004017 nuclear receptors Proteins 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical class OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229940051223 zetia Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW102134981A 2012-09-27 2013-09-27 脂質異常症治療劑 TWI598098B (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2012214635		2012-09-27

Publications (2)

Publication Number	Publication Date
TW201417811A TW201417811A (zh)	2014-05-16
TWI598098B true TWI598098B (zh)	2017-09-11

Family

ID=50387566

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW102134981A TWI598098B (zh)	2012-09-27	2013-09-27	脂質異常症治療劑

Country Status (20)

Country	Link
US (4)	US9572798B2 (fr)
EP (1)	EP2902025B1 (fr)
JP (1)	JP6238460B2 (fr)
KR (1)	KR102098032B1 (fr)
CN (1)	CN104640544B (fr)
AU (1)	AU2013321918B2 (fr)
BR (1)	BR112015006305B1 (fr)
CA (1)	CA2901650C (fr)
EA (1)	EA024873B1 (fr)
ES (1)	ES2752039T3 (fr)
IL (1)	IL237981B (fr)
IN (1)	IN2015DN02966A (fr)
MX (1)	MX357446B (fr)
MY (1)	MY177686A (fr)
PH (1)	PH12015500471A1 (fr)
PL (1)	PL2902025T3 (fr)
PT (1)	PT2902025T (fr)
SG (1)	SG11201501740XA (fr)
TW (1)	TWI598098B (fr)
WO (1)	WO2014050134A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI691331B (zh) *	2014-09-26	2020-04-21	日商興和股份有限公司	脂質異常症治療劑
KR20200024165A (ko) *	2017-06-30	2020-03-06	교와 가부시키가이샤	의약 조성물
WO2019004448A1 (fr) *	2017-06-30	2019-01-03	興和株式会社	Composition pharmaceutique
JPWO2019004452A1 (ja) *	2017-06-30	2020-04-30	興和株式会社	医薬組成物
US11344535B2 (en)	2017-06-30	2022-05-31	Kowa Company, Ltd.	Pharmaceutical composition
JPWO2019004453A1 (ja) *	2017-06-30	2020-04-30	興和株式会社	医薬品
HUE069648T2 (hu) *	2017-06-30	2025-03-28	Kowa Co	Gyógyszerészeti készítmény
EP3646864B1 (fr)	2017-06-30	2026-04-08	Kowa Company, Ltd.	Composition pharmaceutique contenant du pémafibrate
JP7425603B2 (ja) *	2017-06-30	2024-01-31	興和株式会社	医薬組成物
US11446282B2 (en)	2017-12-21	2022-09-20	Kowa Company, Ltd.	Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20190224169A1 (en) *	2017-12-21	2019-07-25	Kowa Company, Ltd.	Methods of Treatment of Hypertriglyceridemia
EP3903781A4 (fr) *	2018-12-27	2023-01-25	Kowa Company, Ltd.	Préparation pharmaceutique
US20220096443A1 (en) *	2018-12-27	2022-03-31	Kowa Company, Ltd.	Pharmaceutical composition
JP2020105174A (ja) *	2018-12-27	2020-07-09	興和株式会社	医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050101636A1 (en) *	2003-09-03	2005-05-12	Kowa Co., Ltd.	PPAR-activating compound and pharmaceutical composition comprising the compound

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7205321B2 (en)	2001-11-15	2007-04-17	Eli Lilly And Company	Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en)	2003-05-21	2006-01-17	Pfizer Inc.	Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2005009942A1 (fr)	2003-07-28	2005-02-03	Kyorin Pharmaceutical Co., Ltd.	Derive d'acide phenylpropionique substitue optiquement actif
CN100425594C (zh) *	2003-09-03	2008-10-15	兴和株式会社	Ppar活性化化合物及含该化合物的医药组合物
DE102004016845A1 (de)	2004-04-07	2005-10-27	Bayer Healthcare Ag	Phenylthioessigsäure-Derivate und ihre Verwendung
US7629372B2 (en)	2004-09-16	2009-12-08	Merck & Co., Inc.	Compounds for the treatment of dyslipidemia and other lipid disorders
TWI359810B (en)	2004-11-04	2012-03-11	Mitsubishi Tanabe Pharma Corp	Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (fr)	2005-07-08	2007-01-18	Kalypsys, Inc	Agents modificateurs de l'absorption du cholesterol cellulaire
WO2007008541A2 (fr)	2005-07-08	2007-01-18	Kalypsys, Inc.	Modificateurs d'absorption de cholesterol cellulaire
US7795291B2 (en)	2006-07-07	2010-09-14	Bristol-Myers Squibb Company	Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CA2663502A1 (fr)	2006-09-15	2008-03-20	Schering Corporation	Derives d'azetidinone et procedes d'utilisation de ceux-ci
WO2008104875A1 (fr)	2007-03-01	2008-09-04	Pfizer Products Inc.	Oxazolidinones comme inhibiteurs d'absorption de cholestérol
TWI407955B (zh) *	2007-03-29	2013-09-11	Kowa Co	高脂血症之預防及／或治療劑
WO2009047240A1 (fr)	2007-10-09	2009-04-16	Smithkline Beecham Corporation	Dérivés d'indole utiles comme activateurs de ppar
DE102007061757A1 (de)	2007-12-20	2009-06-25	Bayer Healthcare Ag	Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

2013
- 2013-09-27 KR KR1020157005248A patent/KR102098032B1/ko active Active
- 2013-09-27 AU AU2013321918A patent/AU2013321918B2/en not_active Ceased
- 2013-09-27 EA EA201590653A patent/EA024873B1/ru unknown
- 2013-09-27 MY MYPI2015700727A patent/MY177686A/en unknown
- 2013-09-27 JP JP2014538198A patent/JP6238460B2/ja active Active
- 2013-09-27 IN IN2966DEN2015 patent/IN2015DN02966A/en unknown
- 2013-09-27 ES ES13842381T patent/ES2752039T3/es active Active
- 2013-09-27 US US14/429,449 patent/US9572798B2/en active Active
- 2013-09-27 BR BR112015006305-5A patent/BR112015006305B1/pt active IP Right Grant
- 2013-09-27 CN CN201380047997.XA patent/CN104640544B/zh active Active
- 2013-09-27 PL PL13842381T patent/PL2902025T3/pl unknown
- 2013-09-27 TW TW102134981A patent/TWI598098B/zh active
- 2013-09-27 SG SG11201501740XA patent/SG11201501740XA/en unknown
- 2013-09-27 MX MX2015003705A patent/MX357446B/es active IP Right Grant
- 2013-09-27 EP EP13842381.9A patent/EP2902025B1/fr active Active
- 2013-09-27 CA CA2901650A patent/CA2901650C/fr active Active
- 2013-09-27 WO PCT/JP2013/005756 patent/WO2014050134A1/fr not_active Ceased
- 2013-09-27 PT PT138423819T patent/PT2902025T/pt unknown
2015
- 2015-03-04 PH PH12015500471A patent/PH12015500471A1/en unknown
- 2015-03-26 IL IL237981A patent/IL237981B/en active IP Right Grant
2017
- 2017-01-06 US US15/399,856 patent/US9931321B2/en active Active
2018
- 2018-02-26 US US15/904,922 patent/US10258609B2/en active Active
2019
- 2019-02-11 US US16/272,050 patent/US11013722B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050101636A1 (en) *	2003-09-03	2005-05-12	Kowa Co., Ltd.	PPAR-activating compound and pharmaceutical composition comprising the compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JM. McKenney,et al."Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia",Journal of the American College of Cardiology,Vol. 47, No. 8,1584–7 ,2006. *
U Syversen1,et al"Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone",BMC Endocrine Disorders, 30 March 2009, 9:10. *

Also Published As

Publication number	Publication date
KR20150063035A (ko)	2015-06-08
AU2013321918B2 (en)	2018-05-10
PH12015500471B1 (en)	2015-04-20
EP2902025B1 (fr)	2019-08-07
HK1206620A1 (zh)	2016-01-15
JP6238460B2 (ja)	2017-11-29
US9572798B2 (en)	2017-02-21
US20190167645A1 (en)	2019-06-06
EP2902025A4 (fr)	2016-03-02
MX357446B (es)	2018-07-10
MX2015003705A (es)	2015-06-10
IL237981A0 (en)	2015-05-31
US20180185337A1 (en)	2018-07-05
EA024873B1 (ru)	2016-10-31
CA2901650C (fr)	2021-05-04
CN104640544A (zh)	2015-05-20
US10258609B2 (en)	2019-04-16
CN104640544B (zh)	2017-05-03
US20150196538A1 (en)	2015-07-16
BR112015006305A2 (pt)	2017-07-04
BR112015006305B1 (pt)	2020-11-17
TW201417811A (zh)	2014-05-16
IL237981B (en)	2020-05-31
ES2752039T3 (es)	2020-04-02
EP2902025A1 (fr)	2015-08-05
PL2902025T3 (pl)	2020-03-31
IN2015DN02966A (fr)	2015-09-18
PH12015500471A1 (en)	2015-04-20
WO2014050134A1 (fr)	2014-04-03
US9931321B2 (en)	2018-04-03
KR102098032B1 (ko)	2020-04-07
US20170112811A1 (en)	2017-04-27
AU2013321918A1 (en)	2015-04-23
EA201590653A1 (ru)	2015-07-30
CA2901650A1 (fr)	2014-04-03
SG11201501740XA (en)	2015-04-29
US11013722B2 (en)	2021-05-25
PT2902025T (pt)	2019-11-04
JPWO2014050134A1 (ja)	2016-08-22
MY177686A (en)	2020-09-23

Publication	Publication Date	Title
TWI598098B (zh)	2017-09-11	脂質異常症治療劑
JP6761346B2 (ja)	2020-09-23	脂質異常症治療剤
CN106714798B (zh)	2020-11-06	血脂异常症治疗剂
HK1206620B (en)	2018-03-29	Therapeutic agent for dyslipidemia
WO2024010030A1 (fr)	2024-01-11	Agent destiné à réduire le taux de myostatine dans le sang
HK1237263A1 (en)	2018-04-13	Dyslipidemia therapeutic agent